ArticleCureus2025
The Role of Dupilumab in Atopic Dermatitis-Like Graft-Versus-Host Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging Paediatric Uses of Dupilumab Beyond Approvals.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis-like graft-versus-host disease (AD-like GVHD) is a rare but challenging complication following hematopoietic stem cell transplantation (HSCT), mimicking features of atopic dermatitis (AD) and often requiring prolonged immunosuppression. We report the case of a 14-year-old girl with a history of mild AD and post-HSCT GVHD involving skin and the gastrointestinal tract, presenting with severe pruritus, extensive eczema, and significant impact on quality of life. Standard treatment with corticosteroids and immunosuppressants yielded suboptimal results and notable side effects, including growth retardation. After multidisciplinary evaluation, off-label treatment with dupilumab was initiated, resulting in significant clinical improvement, corticosteroid tapering, and enhanced quality of life. This case highlights the potential role of dupilumab as a safe and effective corticosteroid-sparing therapy for AD-like GVHD in pediatric patients, although further studies are needed to confirm its long-term safety and efficacy in transplant settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.